(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let’s ...
The 104-week findings build on the previously reported 39-week results, published in The New England Journal of Medicine in May 2026, and extend the evidence from proteinuria reduction to longer-term ...
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third ...
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, ...
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume. Aardvark will host a webcast to review available dataset from the terminated Phase 3 HER ...
In a release issued under the same headline earlier today, please note that in the third paragraph of the release, the "Reverse Stock Split date" should be "October 26, 2026," not "October 19, 2026," ...
The Delta Dental Foundation of North Carolina today announced a $1 million commitment to expand access to oral health care and strengthen the state’s dental workforce. The Foundation’s investment will ...
Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse split (the “Reverse Split”) of its ...
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at ...
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia. Highlights. Collaboration aims to accelerate precision oncology r ...
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third ...
The conference call can be accessed using the following information: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results